Trials / Temporarily Not Available
Temporarily Not AvailableNCT05221619
Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
Nipocalimab Post-trial Access in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA) Who Are Experiencing Clinical Benefit After Complete 28-Weeks Open-label Extension in MOM-M281-006
- Status
- Temporarily Not Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- —
Summary
The purpose of this post-trial access (PTA) program is to provide nipocalimab for the treatment of participants with Warm Autoimmune Hemolytic Anemia (wAIHA) who are experiencing clinical benefit after completing 28-weeks open-label extension in MOM-M281-006 (NCT04119050) study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nipocalimab | Depending on the dose received at their last administration in the MOM-M281-006 (NCT04119050) study, participants will continue to receive either nipocalimab dose-1 every 2 weeks (Q2W) or nipocalimab dose-2 every 4 weeks (Q4W) by intravenous (IV) infusion. |
Timeline
- First posted
- 2022-02-03
- Last updated
- 2026-01-16
Source: ClinicalTrials.gov record NCT05221619. Inclusion in this directory is not an endorsement.